In the world of opioid addiction treatment, the hardest moment often arrives precisely when hope begins to emerge. It is the moment someone chooses to stop using opioids. That decision, courageous and life-changing, almost immediately collides with one of the most punishing physiologic syndromes known in medicine: opioid withdrawal. Withdrawal brings waves of nausea, sweats, shaking, cramps, insomnia, anxiety, and extremely intense cravings. For countless individuals, this moment is a seemingly inescapable stumbling block that can be the undoing of their recovery. They want to stop, they mean to stop, but withdrawal can become an insurmountable barrier.

Across the world, scientists are still trying to answer one of medicine’s most difficult questions: how can we safely and effectively treat brain cancers such as glioma? Despite decades of effort, outcomes for people diagnosed with high-grade glioma remain bleak. Current treatments, including surgery, radiotherapy, and chemotherapy, can slow the disease, but rarely stop it. The GlioLighT consortium, a multidisciplinary European research team funded by the European Innovation Council, has come together to explore a novel approach based on direct light therapy. Being in a very early stage, the project doesn’t promise an immediate cure; instead, it sets out to answer a very fundamental question: can light itself trigger biological processes that might form the basis of a safe and targeted brain tumor therapy?